Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
LiGeR - HN1
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
- NCT06525220 ↗
- Active, not recruiting
- Merus B.V.
- Focused
We haven't built an HCP commentary report on LiGeR - HN1 (petosemtamab and pembrolizumab in Head and Neck Squamous Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LiGeR - HN1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Petosemtamab; Pembrolizumab
- Arms
- Petosemtamab + Pembrolizumab · Experimental
- Pembrolizumab · Active comparator
- Enrollment
- 699
- Primary outcomes
- Overall Survival (OS)
- Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)
- Sponsor
- Merus B.V.
- Start
- Sep 25, 2024
- Primary completion
- Jan 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06525220 · updated Sep 25, 2026
Publications
linked from the registry- Machiels JP, Fayette J, Haddad R, Adkins D, Gillison M, Harrington KJ, Kim SB, Le Tourneau C, Psyrri A, Rosenberg A, Siu LL, Tahara M, William WN Jr, Ford J, Jauhari S, Pyle R, Shen YM, Yao D, Zohren F, Vokes E. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC. Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13. PubMed 40511820